Michael Molhoj

USPTO Granted Patents = 26 (Patent Applications = 24)

CIPO Patents = 4 (Patent Applications = 8)

EPO Patents = 16 (Patent Applications = 25)

Average Co-Inventor Count = 8.5

ph-index = 5

Forward Citations = 67(Granted Patents)

Location History:

Penzberg, DE (2023)
Munich, DE (2018 - 2024)

Company Filing History:

21 out of 4,942

Hoffmann-la Roche Inc.

patents

2 out of 75

Amgen Research (munich) Gmbh

Bristol-myers Squibb Compnay

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

26 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12358997 - Bispecific anti-human A-beta/anti-human transferrin receptor antibodies (2025-07-15),

2. 12297263 - Humanized anti-Tau(PS422) antibodies and methods of use (2025-05-13),

3. 12287335 - Direct affinity measurement of human IgG1 binding multimeric antigens (2025-04-29),

4. 12215152 - Humanized anti-human CD19 antibodies and methods of use (2025-02-04),

5. 12030952 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2024-07-09),

6. 11958912 - Method for determining the in vivo interaction mode (2024-04-16),

7. 11952421 - Bispecific antibodies against CD3EPSILON and ROR1 (2024-04-09),

8. 11787868 - Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use (2023-10-17),

9. 11732036 - Antibody that binds to VEGF-A and ANG2 and methods of use (2023-08-22),

10. 11603411 - Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (2023-03-14),

11. 11572404 - Humanized anti-Tau(pS422) antibodies and methods of use (2023-02-07),

12. 11486882 - Method for detecting multispecific antibody light chain mispairing (2022-11-01),

13. 11286300 - Humanized anti-human CD19 antibodies and methods of use (2022-03-29),

14. 11117965 - Bispecific T cell activating antigen binding molecules (2021-09-14),

15. 10941205 - Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use (2021-03-09),

Title: Michael Molhoj: A Pioneer in Antibody Innovations

Introduction

Michael Molhoj, an inventive force in the field of biotechnology, is based in Munich, Germany. With an impressive portfolio of 23 patents, he has made significant contributions to the development of innovative antibodies, particularly in the realm of cancer treatment.

Latest Patents

Among his latest groundbreaking patents are:

1. **Humanized anti-human CD19 antibodies and methods of use** - This patent reports an antibody that specifically binds to human CD19, comprising various specific amino acid sequences that enhance its efficacy and utility in medical applications.

2. **Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use** - This invention includes the development of bispecific antibodies that can target both CD20 and the human transferrin receptor, highlighting new methods for therapeutic interventions.

Career Highlights

Michael has had a distinguished career, contributing his expertise at reputable companies such as Hoffmann-La Roche Inc. and Amgen Research (Munich) GmbH. His work in these organizations has led to advancements in antibody treatments that are critical to modern medical practices.

Collaborations

Throughout his career, Michael has collaborated with talented individuals such as Joerg Thomas Regula and Christian Klein. These partnerships have further enriched his work and the innovations stemming from their collective expertise.

Conclusion

In summary, Michael Molhoj stands out as a significant inventor in the biotechnology sector. His contributions through numerous patents and collaborations have advanced the field of antibody research and development, promising better medical treatments for a range of ailments.

This text is generated by artificial intelligence and may not be accurate.